-
Something wrong with this record ?
Endothelin type A receptor blockade increases renoprotection in congestive heart failure combined with chronic kidney disease: Studies in 5/6 nephrectomized rats with aorto-caval fistula
P. Kala, Z. Vaňourková, P. Škaroupková, E. Kompanowska-Jezierska, J. Sadowski, A. Walkowska, J. Veselka, M. Táborský, H. Maxová, I. Vaněčková, L. Červenka
Language English Country France
Document type Journal Article
- MeSH
- Endothelin A Receptor Antagonists * pharmacology therapeutic use MeSH
- Renal Insufficiency, Chronic * complications drug therapy metabolism MeSH
- Endothelin-1 metabolism MeSH
- Angiotensin-Converting Enzyme Inhibitors pharmacology therapeutic use MeSH
- Rats MeSH
- Kidney MeSH
- Fistula * metabolism MeSH
- Rats, Transgenic MeSH
- Receptor, Endothelin A metabolism MeSH
- Renin-Angiotensin System MeSH
- Heart Failure * drug therapy etiology metabolism MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Association of congestive heart failure (CHF) and chronic kidney disease (CKD) worsens the patient's prognosis and results in poor survival rate. The aim of this study was to examine if addition of endothelin type A (ETA) receptor antagonist to the angiotensin-converting enzyme inhibitor (ACEi) will bring additional beneficial effects in experimental rats. METHODS: CKD was induced by 5/6 renal mass reduction (5/6 NX) and CHF was elicited by volume overload achieved by creation of aorto-caval fistula (ACF). The follow-up was 24 weeks after the first intervention (5/6 NX). The treatment regimens were initiated 6 weeks after 5/6 NX and 2 weeks after ACF creation. RESULTS: The final survival in untreated group was 15%. The treatment with ETA receptor antagonist alone or ACEi alone and the combined treatment improved the survival rate to 64%, 71% and 75%, respectively, however, the difference between the combination and either single treatment regimen was not significant. The combined treatment exerted best renoprotection, causing additional reduction in albuminuria and reducing renal glomerular and tubulointerstitial injury as compared with ACE inhibition alone. CONCLUSIONS: Our results show that treatment with ETA receptor antagonist attenuates the CKD- and CHF-related mortality, and addition of ETA receptor antagonist to the standard blockade of RAS by ACEi exhibits additional renoprotective actions.
Department of Pathophysiology 2nd Faculty of Medicine Charles University Prague Czech Republic
Institute of Physiology Czech Academy of Sciences Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004325
- 003
- CZ-PrNML
- 005
- 20230425141306.0
- 007
- ta
- 008
- 230418s2023 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.biopha.2022.114157 $2 doi
- 035 __
- $a (PubMed)36580726
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Kala, Petr $u Department of Cardiology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic; Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Electronic address: petrkala@gmail.com
- 245 10
- $a Endothelin type A receptor blockade increases renoprotection in congestive heart failure combined with chronic kidney disease: Studies in 5/6 nephrectomized rats with aorto-caval fistula / $c P. Kala, Z. Vaňourková, P. Škaroupková, E. Kompanowska-Jezierska, J. Sadowski, A. Walkowska, J. Veselka, M. Táborský, H. Maxová, I. Vaněčková, L. Červenka
- 520 9_
- $a BACKGROUND: Association of congestive heart failure (CHF) and chronic kidney disease (CKD) worsens the patient's prognosis and results in poor survival rate. The aim of this study was to examine if addition of endothelin type A (ETA) receptor antagonist to the angiotensin-converting enzyme inhibitor (ACEi) will bring additional beneficial effects in experimental rats. METHODS: CKD was induced by 5/6 renal mass reduction (5/6 NX) and CHF was elicited by volume overload achieved by creation of aorto-caval fistula (ACF). The follow-up was 24 weeks after the first intervention (5/6 NX). The treatment regimens were initiated 6 weeks after 5/6 NX and 2 weeks after ACF creation. RESULTS: The final survival in untreated group was 15%. The treatment with ETA receptor antagonist alone or ACEi alone and the combined treatment improved the survival rate to 64%, 71% and 75%, respectively, however, the difference between the combination and either single treatment regimen was not significant. The combined treatment exerted best renoprotection, causing additional reduction in albuminuria and reducing renal glomerular and tubulointerstitial injury as compared with ACE inhibition alone. CONCLUSIONS: Our results show that treatment with ETA receptor antagonist attenuates the CKD- and CHF-related mortality, and addition of ETA receptor antagonist to the standard blockade of RAS by ACEi exhibits additional renoprotective actions.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a inhibitory ACE $x farmakologie $x terapeutické užití $7 D000806
- 650 12
- $a antagonisté endotelinového receptoru A $x farmakologie $x terapeutické užití $7 D065130
- 650 _2
- $a endotelin-1 $x metabolismus $7 D019332
- 650 12
- $a píštěle $x metabolismus $7 D005402
- 650 12
- $a srdeční selhání $x farmakoterapie $x etiologie $x metabolismus $7 D006333
- 650 _2
- $a ledviny $7 D007668
- 650 _2
- $a potkani transgenní $7 D055647
- 650 _2
- $a receptor endotelinu A $x metabolismus $7 D044022
- 650 12
- $a chronická renální insuficience $x komplikace $x farmakoterapie $x metabolismus $7 D051436
- 650 _2
- $a renin-angiotensin systém $7 D012084
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vaňourková, Zdenka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Škaroupková, Petra $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Kompanowska-Jezierska, Elżbieta $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Institute, Polish Academy of Science, Warsaw, Poland
- 700 1_
- $a Sadowski, Janusz $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Institute, Polish Academy of Science, Warsaw, Poland
- 700 1_
- $a Walkowska, Agnieszka $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Institute, Polish Academy of Science, Warsaw, Poland
- 700 1_
- $a Veselka, Josef $u Department of Cardiology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Táborský, Miloš $u Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacký University, Olomouc, Czech Republic
- 700 1_
- $a Maxová, Hana $u Department of Pathophysiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Vaněčková, Ivana $u Institute of Physiology, Czech Academy of Sciences, Czech Republic
- 700 1_
- $a Červenka, Luděk $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacký University, Olomouc, Czech Republic
- 773 0_
- $w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 158, č. - (2023), s. 114157
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36580726 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141302 $b ABA008
- 999 __
- $a ok $b bmc $g 1924793 $s 1190534
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 158 $c - $d 114157 $e 20221227 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
- LZP __
- $a Pubmed-20230418
